UMMS Affiliation

Department of Medicine, Division of Cardiovascular Medicine; UMass Center for Clinical and Translational Science; Program in Molecular Medicine

Publication Date


Document Type



Clinical Trials | Infectious Disease | International Business | International Public Health | Technology and Innovation | Virus Diseases


The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities.


clinical trials, covid-19, decentralization, deglobalization, emerging technologies, healthcare, UMCCTS funding

Rights and Permissions

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license’s legal deed at and legal code at for more information.

DOI of Published Version



Dunlap D, Santos RS, McManus DD, Buchholz BO, Hafer NS, Picard M. New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown. AIB Insights. 2020 Nov 3;20(3):10.46697/001c.17692. doi: 10.46697/001c.17692. PMID: 34413924; PMCID: PMC8372191. Link to article on publisher's site

Journal/Book/Conference Title

AIB insights

Related Resources

Link to Article in PubMed

PubMed ID


Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.